Pfizer, Inc. (NYSE:PFE) issued an update on its FY17 earnings guidance on Tuesday morning. The company provided EPS guidance of $2.58-2.62 for the period, compared to the Thomson Reuters consensus EPS estimate of $2.56. The company issued revenue guidance of $52.4-53.1 billion, compared to the consensus revenue estimate of $52.76 billion.
Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, October 31st. The biopharmaceutical company reported $0.67 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.65 by $0.02. The company had revenue of $13.17 billion during the quarter, compared to analyst estimates of $13.17 billion. Pfizer had a return on equity of 25.67% and a net margin of 18.69%. The company’s revenue for the quarter was up .9% compared to the same quarter last year. During the same period in the previous year, the company earned $0.61 EPS.
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, December 1st. Investors of record on Friday, November 10th will be given a $0.32 dividend. The ex-dividend date is Thursday, November 9th. This represents a $1.28 annualized dividend and a dividend yield of 3.65%. Pfizer’s dividend payout ratio is presently 79.01%.
Several equities analysts recently issued reports on PFE shares. Credit Suisse Group lowered Pfizer from an outperform rating to a neutral rating and decreased their price objective for the company from $38.00 to $36.00 in a research report on Thursday, July 20th. BMO Capital Markets reiterated a buy rating and issued a $37.00 price objective on shares of Pfizer in a research report on Wednesday, September 6th. Zacks Investment Research upgraded Pfizer from a sell rating to a hold rating in a research report on Friday, July 14th. Vetr lowered Pfizer from a buy rating to a hold rating and set a $35.71 price objective for the company. in a research report on Wednesday, September 13th. Finally, Morgan Stanley raised Pfizer from an equal weight rating to an overweight rating and upped their price target for the stock from $35.00 to $39.00 in a research report on Wednesday, September 20th. Two research analysts have rated the stock with a sell rating, nine have given a hold rating and thirteen have assigned a buy rating to the stock. The company has a consensus rating of Hold and an average target price of $38.35.
In related news, insider Alexander R. Mackenzie sold 15,000 shares of the firm’s stock in a transaction dated Monday, August 7th. The stock was sold at an average price of $33.50, for a total value of $502,500.00. Following the sale, the insider now directly owns 151,474 shares of the company’s stock, valued at $5,074,379. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Sally Susman sold 38,230 shares of the firm’s stock in a transaction dated Tuesday, September 12th. The shares were sold at an average price of $35.00, for a total value of $1,338,050.00. Following the completion of the sale, the insider now directly owns 145,649 shares in the company, valued at $5,097,715. The disclosure for this sale can be found here. Over the last three months, insiders have sold 464,521 shares of company stock worth $15,813,961. 0.06% of the stock is currently owned by insiders.
WARNING: “Pfizer, Inc. (PFE) Issues FY17 Earnings Guidance” was first reported by Community Financial News and is owned by of Community Financial News. If you are accessing this report on another site, it was illegally stolen and reposted in violation of United States and international copyright and trademark legislation. The legal version of this report can be viewed at https://www.com-unik.info/2017/11/02/pfizer-inc-pfe-issues-fy17-earnings-guidance.html.
A number of large investors have recently added to or reduced their stakes in the stock. Peregrine Asset Advisers Inc. boosted its stake in Pfizer by 0.5% in the second quarter. Peregrine Asset Advisers Inc. now owns 7,354 shares of the biopharmaceutical company’s stock valued at $247,000 after buying an additional 35 shares in the last quarter. Northwest Quadrant Wealth Management LLC boosted its stake in Pfizer by 0.8% in the second quarter. Northwest Quadrant Wealth Management LLC now owns 6,329 shares of the biopharmaceutical company’s stock valued at $211,000 after buying an additional 50 shares in the last quarter. Stone House Investment Management LLC boosted its stake in Pfizer by 1.0% in the second quarter. Stone House Investment Management LLC now owns 7,236 shares of the biopharmaceutical company’s stock valued at $243,000 after buying an additional 72 shares in the last quarter. Highland Private Wealth Management boosted its stake in Pfizer by 0.8% in the second quarter. Highland Private Wealth Management now owns 9,047 shares of the biopharmaceutical company’s stock valued at $304,000 after buying an additional 76 shares in the last quarter. Finally, Autus Asset Management LLC boosted its stake in Pfizer by 1.2% in the second quarter. Autus Asset Management LLC now owns 6,681 shares of the biopharmaceutical company’s stock valued at $225,000 after buying an additional 78 shares in the last quarter. 69.01% of the stock is currently owned by institutional investors and hedge funds.
Pfizer Company Profile
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
What are top analysts saying about Pfizer Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Pfizer Inc. and related companies.